Theravance biopharma | Sustainability Performance
Develops and commercializes biopharmaceutical products, focusing on therapies for respiratory and other diseases. Engages in research, clinical trials, and regulatory submissions for new drug candidates.
2013
United States
51 - 200 employees
Biotechnology
$100M - 500M in revenue
$100M - 500M in profitability
Sustainability Ranking & Industry Benchmark
#6928
Overall#1493
in United States#138
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$64.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
57.8%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-27.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.1
▼ 3.5%
0.1
▼ 2.9%
0.1
▲ 0.0%
0.3
2031Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
62%
Independent Directors
8 out of 13 incl. management
Overall score
54
Environment
62
Social
27
Governance
74
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
